Business
MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of Directors
MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of Directors.
About this update from Metastat Inc
[{"type":"text","content":"\n \n MetaStat, Inc. (OTCQB:MTST), a pre-commercial biotechnology \n company focused on the development and commercialization of companion \n diagnostics and anti-metastatic therapeutics in the novel cancer \n treatments in drugs, today announced the promotion of Jerome B. Zeldis, \n M.D., Ph.D. from Vice Chairman to Chairman and the appointment of \n Douglas A. Hamilton, MetaStat’s President and Chief Executive Officer, \n to its board of directors in connection with a restructuring of \n MetaStat’s board.\n \n \n Dr. Zeldis stated, “MetaStat has an exciting technology platform based \n on the novel mechanisms that drive cancer metastasis and overcome tumor \n resistance to certain therapeutics, creating the potential to discover \n novel cancer drugs. I look forward to working with Doug and the MetaStat \n team in solidifying our mission to discover and develop truly novel \n approaches for treating a variety of cancers.”\n \n \n Mr. Hamilton said, “I am delighted Jerry is leading MetaStat’s Board of \n Directors and honored to serve on the board with him. We have a shared \n vision for the future of the Company, seeing multiple opportunities to \n make significant advances in treating cancer.” Mr. Hamilton continued, \n “Our driver-based diagnostic biomarkers are also therapeutic targets for \n the development of anti-metastatic drugs and combination therapies to \n overcome drug resistance. We plan to leverage our driver-based \n biomarkers and expand strategic partnerships to unlock opportunities in \n oncology.”\n \n \n Please see the company’s current report on Form 8-K filed with the \n Securities and Exchange Commission on May 8, 2017 for full details on \n the board restructuring, including the resignations of Messrs. Berman, \n Goodeve and Bronsther.\n \n \n Dr. Zeldis is the Chief Medical Officer of Sorrento Therapeutics, Inc., \n and previously served as Chief Medical Officer of Celgene Corporation \n and Chief Executive Officer of Celgene Global Health until June 2016. \n Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz \n Research Institute and Janssen Research Institute in both clinical \n research and medical affairs. He currently serves as Chairman of the \n board of Alliqua and Trek Therapeutics, in addition to board positions \n ...